Firebrand Therapeutics Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • 2ndary - Private

Firebrand Therapeutics General Information

Description

Provider of drug discovery and development services intended to develop therapies to treat cancer metastasis. The company's services include research focused on understanding molecular mechanisms of cancer metastasis by applying modern molecular biology, genomics, and computational biology approaches, enabling oncologists to treat cancer from an early stage.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • 174 Nassau Street
  • Suite 331
  • Princeton, NJ 08542
  • United States
+1 (609) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Firebrand Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Secondary Transaction - Private 01-Apr-2023 00.00 Completed Startup
1. Seed Round 10-Jun-2015 00.00 00.00 0000 Completed Startup
To view Firebrand Therapeutics’s complete valuation and funding history, request access »

Firebrand Therapeutics Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Seed 0,000,000 00.000000 00.0 00.0 00 00.0 00.000
To view Firebrand Therapeutics’s complete cap table history, request access »

Firebrand Therapeutics Patents

  • 4

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 000

    Granted

  • 1

    Pending

  • 000

    Expiring in next 12 mo

Firebrand Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2020345037-A1 Inhibitor of metadherin expression Pending 13-Sep-2019 000000000
CA-3150897-A1 Inhibitor of metadherin expression Pending 13-Sep-2019 000000000
EP-3791930-A1 Inhibitor of metadherin expression Pending 13-Sep-2019 000000000 0
US-20230067620-A1 Inhibitor of metadherin expression Pending 13-Sep-2019 C12N15/1138

Firebrand Therapeutics Executive Team (2)

Name Title Board Seat Contact Info
John Jin Co-Founder, Chief Executive Officer & Board Member
Yibin Kang Ph.D Co-Founder, Executive Officer & Board Member
To view Firebrand Therapeutics’s complete executive team members history, request access »

Firebrand Therapeutics Board Members (2)

Name Representing Role Since
John Jin Firebrand Therapeutics Co-Founder, Chief Executive Officer & Board Member 000 0000
Yibin Kang Ph.D Self Co-Founder, Executive Officer & Board Member 000 0000
To view Firebrand Therapeutics’s complete board members history, request access »

Ready to get started?

Request a free trial